Tadalafil in the management of severe pulmonary artery hypertension

Indian Heart Journal

Volumn 58, Issue 1, 2006, Pages 52-53

  Singh, Thokchom S D ^a,c   Kumar, Dilip ^b   Basu, Soumik ^b   Panja, Manotosh ^b   Mitra, Biswanath ^b  

^a REGIONAL INSTITUTE OF MEDICAL SCIENCES   (India)

^b INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^c Sagolband Meinoleirak   (India)

Author keywords

Pulmonary arterial hypertension; Tadalafil

Indexed keywords

BOSENTAN; PROSTACYCLIN; SILDENAFIL; TADALAFIL; WARFARIN;

ABSENCE OF SIDE EFFECTS; ADULT; ANAMNESIS; ARTICLE; BLOOD ANALYSIS; CASE REPORT; DISEASE SEVERITY; DOSE RESPONSE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; FLUSHING; FOLLOW UP; HUMAN; LUNG FUNCTION TEST; MALE; PULMONARY HYPERTENSION; RISK FACTOR; SIDE EFFECT; THORAX RADIOGRAPHY;

EID: 33745817385     PISSN: 00194832     EISSN: 00194832     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. British cardiac society guidelines and medical practice committee, and approved by the British Thoracic Society and the British Society of Rheumatology. Recommendation on the management of pulmonary hypertension in clinical practice. Heart 2001; 86: i1-i3.
2. Kothari SS, Bahl VK. Primary pulmonary hypertension - an update. Indian Heart J 2002; 54: 255-60.
3. Watanable H, Ohasi K, Takeuchi K, Yamashita K, Yokoyama T, Tran QK, et al. Sildenafil for primary and secondary pulmonary hypertension. Clin Pharmacol 2002; 71: 398-402.
4. Bharani A, Mathew V, Sahu A, Lunia B. The efficiency and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension. Indian Heart J 2003; 55: 55-59.
5. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-49.
6. Higgenbotam TW, Spiegelhaltor D, Scott JP, Fuster V, Dinh-Xuan AT, Caine N, et al. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. Br Heart J 1993; 70: 366-70.
7. Turko IV, Ballard SA, Francis SH, Corbin JD. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds. Mol Pharmacol 1999; 56: 124-30.
8. Kothari SS, Duggal B. Chronic oral sildenafil in severe pulmonary artery hypertension. Indian Heart J 2002; 54: 404-09.
9. Sastry BKS, Narasemhan C, Reddy NK, Anand B, Prakash GS, Raju PR, et al. A study of sildenafil in patients with primary pulmonary hypertension. Indian Heart J 2002; 54: 410-14.
10. Eardley I, Cartledge J. Tadalafil (Cialis) for men with erectile dysfunction. Int J Clin Pract 2002; 56: 300-04.